Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 14;42(1):155.
doi: 10.1007/s00345-024-04798-5.

Predicting individual outcomes after radical cystectomy in urothelial variants with Cancer of the Bladder Risk Assessment (COBRA) score

Caio Vinícius Suartz  1 , Maurício Dener Cordeiro  2 , Luiz Antonio Assan Botelho  2 , Fábio Pescarmona Gallucci  2 , David Hamilton Cho  2 , Filipe de Arruda Pessoa  2 , Flávio Rossi da Silva  2 , Mateus Silva Santos Costa  2 , Leonardo Cardili  2 , François Audenet  3 , José Maurício Mota  4 , Paul Toren  5 , William Carlos Nahas  2 , Leopoldo Alves Ribeiro-Filho  2
Affiliations

Predicting individual outcomes after radical cystectomy in urothelial variants with Cancer of the Bladder Risk Assessment (COBRA) score

Caio Vinícius Suartz et al. World J Urol. .

Abstract

Objective: To validate the Cancer of the Bladder Risk Assessment (COBRA) score in patients with urothelial variants.

Methods: Epidemiological, clinical, radiological, and anatomopathological data were collected from patients with urothelial carcinoma who underwent radical cystectomy at the Institute of Cancer of São Paulo between May 2008 and December 2022. Patients with the presence of at least 10% of any urothelial variants in the radical cystectomy specimens' anatomopathological exam were included in the study. The COBRA score and derivatives were applied and correlated with oncological outcomes.

Results: A total of 680 patients [482 men (70.9%) and 198 women (29.1%)]; 66 years (IQR 59-73) underwent radical cystectomy for bladder tumor, and of these patients, a total of 167 patients presented any type of urothelial variant. The median follow-up time was 28.77 months (IQR 12-85). The three most prevalent UV were squamous differentiation (50.8%), glandular differentiation (31.3%), and micropapillary differentiation (11.3%). The subtypes with the worst prognosis were sarcomatoid with a median survival of 8 months (HR 1.161; 95% CI 0.555-2.432) and plasmacytoid with 14 months (HR 1.466; 95% CI 0.528-4.070). The COBRA score for patients with micropapillary variants demonstrated good predictive accuracy for OS (log-rank P = 0.009; 95% IC 6.78-29.21) and CSS (log-rank P = 0.002; 95% IC 13.06-26.93).

Conclusions: In our study, the COBRA score proved an effective risk stratification tool for urothelial histological variants, especially for the micropapillary urothelial variant. It may be helpful in the prognosis evaluation of UV patients after radical cystectomy.

Keywords: Bladder cancer; Nomogram; Prognosis; Radical cystectomy; Risk assessment.

PubMed Disclaimer

References

    1. Sanguedolce F, Zanelli M, Palicelli A, Ascani S, Zizzo M, Cocco G, Björnebo L, Lantz A, Falagario UG, Cormio L, Carrieri G (2022) Are we ready to implement molecular subtyping of bladder cancer in clinical practice? Part 1: general issues and marker expression. Int J Mol Sci 23(14):7819. https://doi.org/10.3390/ijms23147819 - DOI - PubMed - PMC
    1. Shapur NK, Katz R, Pode D, Shapiro A, Yutkin V, Pizov G, Appelbaum L, Zorn KC, Duvdevani M, Landau EH, Gofrit ON (2011) Is radical cystectomy mandatory in every patient with variant histology of bladder cancer. Rare Tumors 3(2):e22. https://doi.org/10.4081/rt.2011.e22 - DOI - PubMed - PMC
    1. McConkey DJ, Choi W, Ochoa A, Siefker-Radtke A, Czerniak B, Dinney CP (2015) Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. Hematol Oncol Clin North Am 29(2):377–xi. https://doi.org/10.1016/j.hoc.2014.11.003 - DOI - PubMed
    1. Blanca A, Lopez-Beltran A, Lopez-Porcheron K, Gomez-Gomez E, Cimadamore A, Bilé-Silva A, Gogna R, Montironi R, Cheng L (2023) Risk classification of bladder cancer by gene expression and molecular subtype. Cancers 15(7):2149. https://doi.org/10.3390/cancers15072149 - DOI - PubMed - PMC
    1. Amin MB, Edge SB, Greene FL, Schilsky RL, Gaspar LE, Washington M (2017) AJCC cancer staging manual. Springer, New York

LinkOut - more resources